Drug Delivery

(Image: Getty/Wavebreakmedia)

Q&A

Nemaura to debut 48-hour transdermal pain patch

By Ben Hargreaves

Ahead of the CPhI Worldwide in Madrid next week, Nemaura announced that it would be showcasing its newly developed 48-hour diclofenac transdermal patch and would be linking up with an unnamed global pharma company to develop three new products.

(Image: Getty/Victor_Tongdee)

Ketamine: The future treatment of severe mental illness?

By Maggie Lynch

In this first part of a two-part investigation, we look at how NDMA receptor antagonists, such as ketamine, could be poised to make a breakthrough in the treatment of depression – an area where the pharma industry has struggled to identify new targets...